Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CTAS stock price vs LRCX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LRCX's multiple
Needs LRCX P/E.
Implied fair value · at CTAS's multiple
Needs CTAS P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Cintas Corporation · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
LAM RESEARCH CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
UNIFIRST CORP
CTAS vs UNF
ABM INDUSTRIES INC /DE/
CTAS vs ABM
Aramark
CTAS vs ARMK
W.W. GRAINGER, INC.
CTAS vs GWW
INTUIT INC.
CTAS vs INTU
IRON MOUNTAIN INC
CTAS vs IRM
Applied Materials, Inc.
CTAS vs AMAT
KLA CORP
CTAS vs KLAC
ASML HOLDING NV
CTAS vs ASML
TERADYNE, INC
CTAS vs TER
ENTEGRIS INC
CTAS vs ENTG
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CTAS can justify a valuation well above its $50.25 to $67.98 DCF range through sustained premium margins and better growth, then hold or add; otherwise, reduce exposure because the current $181.37 price already exceeds that cash-flow-based range materially.
CTAS trades at $181.37 versus an implied P/E value of $372.58, suggesting 105.4% upside on the supplied multiple framework, but the broader valuation context is less supportive. Its current price is already above the historical band midpoint and far above the DCF range, which points to a meaningful disconnect between market price and cash-flow-based valuation.
Supporting Metrics
